AutoRIC (CellAegis) receives CE mark for AMI patients

CellAegis has received a CE Mark for its autoRIC device, which allows simple automation of remote ischemic conditioning (RIC) at the point of care for patients with Acute Myocardial Infarction. CellAegis' autoRIC Device has been developed for acute care applications in the ambulance, emergency room and other hospital settings, or for chronic treatment in the home. Remote ischemic conditioning uses sequences of short, controlled periods of reduced or no blood flow (ischemia) in a limb followed by resumed blood flow (reperfusion). By activating innate mechanisms of metabolic protection in the body, RIC has been shown to reduce the larger damage from ischemic reperfusion injury to cardiac and other organs, including myocardial infarctions, cardiac surgery, stroke, trauma, and organ transplantation. Later this year, CellAegis is initiating an international trial of the autoRIC Device in the EU and US in patients who will undergo elective PCI and cardiac surgery, including coronary artery bypass graft surgery. The randomized study will measure decrease in heart damage and mortality in over 1000 patients to be enrolled in multiple clinical centers in the UK, Denmark, Germany and the US. The autoRIC Device is not yet cleared for sale in the US.